118 related articles for article (PubMed ID: 17575799)
1. [Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004].
Kárpati K; Brandtmüller A; Májer I; Gulácsi L
Acta Pharm Hung; 2006; 76(4):191-9. PubMed ID: 17575799
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of annual health insurance reimbursement for oncology drugs in Hungary].
Boncz I; Donkáné Verebes E; Oberfrank F; Kásler M
Magy Onkol; 2010 Dec; 54(4):283-8. PubMed ID: 21163758
[TBL] [Abstract][Full Text] [Related]
3. [Health economics of oncology care: financial effect of performance volume limit (PVL)].
Boncz I; Donkáné Verebes E; Oberfrank F; Kásler M
Magy Onkol; 2010 Mar; 54(1):35-9. PubMed ID: 20350866
[TBL] [Abstract][Full Text] [Related]
4. [Medical problems associated with the national reference pricing system in Hungary].
Kerpel-Fronius S
Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
[TBL] [Abstract][Full Text] [Related]
5. The long-term effect of generic price competition on the Hungarian statin market.
Répásy B; Gazsó T; Elmer D; Pónusz-Kovács D; Kajos FL; Csákvári T; Kovács B; Boncz I
BMC Health Serv Res; 2023 May; 23(1):447. PubMed ID: 37147682
[TBL] [Abstract][Full Text] [Related]
6. Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary.
Hornyák L; Nagy Z; Ilku L; Tálos Z; Endrei D; Ágoston I; Csákvári T; Danku N; Répásy B; Boncz I
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):725-731. PubMed ID: 30763134
[No Abstract] [Full Text] [Related]
7. [Health insurance reimbursement of dental care in Hungary].
Marada G; Nagy A; Benke B; Boncz I
Fogorv Sz; 2012 Mar; 105(1):3-8. PubMed ID: 22530363
[TBL] [Abstract][Full Text] [Related]
8. [Health care costs of acute myocardial infarction in Hungary, 2003-2005].
Gulácsi L; Májer I; Boncz I; Brodszky V; Merkely B; Maurovich HP; Kárpáti K
Orv Hetil; 2007 Jul; 148(27):1259-66. PubMed ID: 17604262
[TBL] [Abstract][Full Text] [Related]
9. [Social insurance costs of hospital treatment of stroke in Hungary, 2003-2005].
Kárpáti K; Májer I; Boncz I; Nagy A; Bereczki D; Gulácsi L
Ideggyogy Sz; 2007 Jul; 60(7-8):311-20. PubMed ID: 17713112
[TBL] [Abstract][Full Text] [Related]
10. Reimbursement for drugs -- a register study comparing economic outcome for five healthcare centres in areas with different socioeconomic conditions.
Semark B; Fredlund K; Astrand B; Brudin L
Scand J Public Health; 2009 Aug; 37(6):647-53. PubMed ID: 19546143
[TBL] [Abstract][Full Text] [Related]
11. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
12. [Effects of performance-volume limit on the institutional financing of the Clinical Centre of the University of Pécs, Hungary].
Endrei D; Kollár L; Bódis J; Imhof G; Zemplényi A; Vas G; Boncz I
Orv Hetil; 2010 Aug; 151(31):1270-4. PubMed ID: 20656665
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical pricing and reimbursement reforms in Greece.
Yfantopoulos J
Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
[TBL] [Abstract][Full Text] [Related]
14. Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
[TBL] [Abstract][Full Text] [Related]
15. [Influence of the reimbursement scheme on the consumption of drugs].
Madsen UK
Ugeskr Laeger; 2009 Mar; 171(10):783-6. PubMed ID: 19265600
[TBL] [Abstract][Full Text] [Related]
16. [Health insurance pharmaceutical expenditures in Hungary].
Eisingerné Balassa B; Csákvári T; Ágoston I
Orv Hetil; 2019 Feb; 160(Suppl 1):49-54. PubMed ID: 30724598
[TBL] [Abstract][Full Text] [Related]
17. [Economic feasibility study and reimbursement rules--illustrated by a concrete example].
Keiding H; Faergeman O
Ugeskr Laeger; 2008 Feb; 170(8):651-4. PubMed ID: 18364159
[TBL] [Abstract][Full Text] [Related]
18. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
19. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
20. Conditional reimbursement within the Dutch drug policy.
Niezen M; de Bont A; Stolk E; Eyck A; Niessen L; Stoevelaar H
Health Policy; 2007 Nov; 84(1):39-50. PubMed ID: 17207886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
